Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF).

Chen, Xuejun

Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). [electronic resource] - Journal of clinical pharmacology Jul 2013 - 721-30 p. digital

Publication Type: Journal Article

1552-4604

10.1002/jcph.102 doi


Aged
Clinical Trials, Phase III as Topic
Double-Blind Method
Female
Humans
Janus Kinases--antagonists & inhibitors
Male
Models, Biological
Nitriles
Polycythemia Vera--drug therapy
Primary Myelofibrosis--drug therapy
Protein Kinase Inhibitors--pharmacokinetics
Pyrazoles--administration & dosage
Pyrimidines
Randomized Controlled Trials as Topic
Thrombocythemia, Essential--drug therapy